CAR T cells against CD19, a component of the BCR complex, can provide significant activity in patients suffering from advanced or refractory CLL but the rate of complete remissions and long-term responses remain well behind that observed in other lymphoma types7–13. This evidence concerns the gene BCR and lymphoma.